Welcome to our dedicated page for Awakn Life Scien news (Ticker: AWKNF), a resource for investors and traders seeking the latest updates and insights on Awakn Life Scien stock.
Awakn Life Sciences Corp. (AWKNF) is a clinical-stage biotechnology company pioneering novel treatments for addiction and mental health disorders. This page provides investors and industry observers with centralized access to official announcements, research developments, and strategic updates.
Track key milestones across Awakn's therapeutic pipeline, including progress in Alcohol Use Disorder (AUD) treatments and trauma-related innovations. Stay informed about clinical trial updates, regulatory submissions, and partnerships with leading research institutions.
Our curated news feed features verified information on:
• Clinical research advancements
• Strategic collaborations
• Regulatory pathway developments
• R&D program expansions
Bookmark this page for reliable updates on Awakn's mission to transform addiction treatment through integrated pharmacological and therapeutic approaches. Check regularly for the latest developments in medication-assisted therapy innovation.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has entered into a licensing partnership with Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF) to implement the KARE® protocol for treating Alcohol Use Disorder. Awakn's ketamine-assisted therapy demonstrates significant improvements over current treatment standards, achieving an 86% abstinence rate in post-treatment trials. Revitalist will incur an annual licensing fee and share revenue from services. The U.S. alcohol treatment industry, worth over $30B, faces high relapse rates, which this partnership aims to address.
FAQ
What is the current stock price of Awakn Life Scien (AWKNF)?
What is the market cap of Awakn Life Scien (AWKNF)?
